Navigation Links
Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
Date:7/29/2008

RICHMOND, Calif., July 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic development programs and an overview of the company's business strategy at 3:00 p.m. (ET) on Tuesday, August 5, 2008, at the BMO Capital Markets Focus on Healthcare Conference in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Other therapeutic development programs are focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
2. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
3. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
4. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
5. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
6. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
7. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
8. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
9. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
10. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
11. Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Four-dimensional (4-D) printing ... based on external stimuli such as changes in ... a disruptive effect in multiple industries.  In the ... landscape by printing objects ranging from human organs ... sectors. Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... 21, 2014 On Wednesday of last week ... use Redox Signaling molecules, became available for purchase in Australia ... "The way that RENU 28 works is, if you think ... of the rate of cellular renewal within your body. If ... of that rate of cellular renewal. What RENU 28 does ...
(Date:8/20/2014)... PLANTATION, Fla. , Aug. 20, 2014 /PRNewswire/ ... it will host a conference call to provide ... 26, 2014Time:4:30 p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 ... number: 9126599 Live web cast: www.neurotropebioscience.com , under ... three hours after completion through September 2, 2014 ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... and NORTH BRUNSWICK, New Jersey, September 14, Rosetta ... in,the development of microRNA-based diagnostics and therapeutics, announced,today ... at Maxim,Group,s Growth conference on Thursday, September 20, ... in New York. A live audio webcast ...
... Boston Scientific,Corporation (NYSE: BSX ) ... 15,000 patients(1) monitored wirelessly on the LATITUDE(R) ... industry,s largest,experience with wireless remote monitoring of ... can detect clinical events between,scheduled follow-up visits ...
... N.J., Sept. 14 Palatin,Technologies, Inc. (Amex: PTN ) ... June 30, 2007. Palatin reported a net loss of,$6.1 million, ... ended,June 30, 2007, compared to a net loss of $7.9 ... period in 2006. Total revenues in the,quarter ended June 30, ...
Cached Biology Technology:Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference 2Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System 2Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System 3Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 3Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 5Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 6Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 7Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007 8
(Date:8/20/2014)... the University of Tbingen, Arizona State University, the Wellcome ... Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... 1000 years old. The pathogen is a relative of ... causes disease in humans today. These researchers assume that ... coast. "The link to sea lions was unexpected" comments ...
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... has awarded the Oklahoma Medical Research Foundation a five-year, ... and the bacteria,s effects on humans. , For ... colleagues have studied the human immune response to anthrax ... Immunology. The original funding came soon after anthrax-laced letters ... the terrorist attacks of Sept. 11, 2001. , ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2
... German . Soil is the most species-rich ... specifically choose certain species, give them access to the root ... which they then benefit in a variety of ways. To ... tell which of these bacteria are friends and which foes. ...
... very low frequency sounds, with pitches below the range ... travel several kilometers, and provide elephants with a "private" ... complex social life. Their frequencies are as low as ... the sounds themselves have been studied for many years, ...
... have demonstrated in the laboratory that a new drug is ... it will be a few years before it becomes available ... UCSB and a biotech firm based in Indiana. The study ... Society of Nephrology . Over 600,000 people in the ...
Cached Biology News:Bacterial community inside the plant root 2Bacterial community inside the plant root 3Mystery of elephant infrasounds revealed 2New drug shows promise for kidney disease 2New drug shows promise for kidney disease 3
...
... Anti-HMGN2/HMG-17 Immunogen : ... Tris-glycine, pH7.4, 5mg/ml BSA, 0.15M ... the addition of glycerol to ... by immunoblot on acid extracts ...
...
... different human fetal normal tissues are ... upon request. Customers can choose ... set, and pay 70% of the ... P Set products are for research ...
Biology Products: